Koninklijke DSM (RDSMY) Raised to Buy at Zacks Investment Research
Koninklijke DSM (OTCMKTS:RDSMY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday. The firm currently has a $27.00 target price on the basic materials company’s stock. Zacks Investment Research‘s price target indicates a potential upside of 8.83% from the company’s current price.
According to Zacks, “DSM N V ADR is involved in the Chemicals Industry. Their main focus is on base materials, performance materials, materials processing, base chemicals and fine chemicals and coating resins. They are also involved in the exploration and development of oil and natural gas deposits in the North Sea, as well as the licensing of chemical technology and know-how; in addition the company produces ingredients for bakery products. DSM is a world market leader in a number of products, including caprolactam, melamine and EPDM synthetic rubber. “
A number of other research analysts have also weighed in on the stock. ValuEngine lowered shares of Koninklijke DSM from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Deutsche Bank raised shares of Koninklijke DSM from a “hold” rating to a “buy” rating in a report on Friday, December 1st. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $27.00.
Koninklijke DSM Company Profile
Koninklijke DSM N.V. (Royal DSM) is a global science-based company, engaged in offering health, nutrition and materials. The Company’s segments include Nutrition, Performance Materials, Innovation Center and Corporate Activities. Its Nutrition segment includes DSM Nutritional Products and DSM Food Specialties.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Koninklijke DSM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Koninklijke DSM and related companies with MarketBeat.com's FREE daily email newsletter.